首页> 外文期刊>Organic process research & development >Development of a New Synthetic Route of a Non-Peptide CCR5 Antagonist, TAK-779, for Large-Scale Preparation
【24h】

Development of a New Synthetic Route of a Non-Peptide CCR5 Antagonist, TAK-779, for Large-Scale Preparation

机译:用于大规模制备的非肽CCR5拮抗剂TAK-779的新合成路线的开发

获取原文
获取原文并翻译 | 示例
           

摘要

A new large-scalable preparation of TAK-779 (1), a non-peptide CCR5 antagonist, has been developed. The route selection was focused on in the process research. The selective reduction of commercially available benzonitrile derivative (4) as the starting material with sodium bis(2-methoxyethoxy)aluminum hydride followed by the Witting reaction, hydrogenation, and intramolecular acylation gave benzocycloheptanone (7) in good yield. The conversion of α,β-unsaturated carboxylic acid (8) led from 7 to benzyl alcohol (9) and shortened the number of steps using non-protected 4-aminobenzyl alcohol. The reductive alkylation of Me_2NH and tetrahydro-4H-pyran-4-one (12) smoothly gave a tertiary amine (3). The coupling of 2 chlorinated 9, and 3 successfully led to an ammonium chloride (1). A new inexpensive preparation which did not require a chromatographic method was achieved.
机译:已开发出一种新的可大规模制备的非肽CCR5拮抗剂TAK-779(1)。路线选择是过程研究中的重点。用双(2-甲氧基乙氧基)氢化铝钠选择性还原作为原料的市售苯甲腈衍生物(4),然后进行Witting反应,氢化和分子内酰化,得到高产率的苯并环庚酮(7)。 α,β-不饱和羧酸(8)从7转化为苯甲醇(9),并使用未保护的4-氨基苯甲醇缩短了步骤数。 Me_2NH和四氢-4H-吡喃-4-酮的还原烷基化(12)平稳地得到叔胺(3)。 2个氯化的9和3的偶联成功生成氯化铵(1)。获得了不需要色谱方法的廉价的新制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号